A Physician-led
Research Company.
VALIDATED THROUGH INDEPENDENT STUDY
A Polyphenol Research Company Built on a Clinical Question
KBS Research is a physician-led research and development company focused on clinically studied, mechanism-driven polyphenol formulations. Founded in 2012 by Dr. Kenneth Brown, MD, and Brandi Scott-Hoy, the company began in a Texas gastroenterology practice where a simple question emerged: why were symptoms improving while the underlying mechanism remained unaddressed?
That question became the foundation for more than a decade of polyphenol research.
Dr. Kenneth Brown had spent more than a decade performing endoscopies and treating patients with bloating, reflux, and chronic gut dysfunction. The pattern was consistent. Patients arrived with real symptoms. They left with a category. IBS. GERD. Functional dyspepsia. Labels that grouped the symptoms but rarely explained what was driving them. So he started asking different questions. Not how to treat the symptom, but what was producing it.
How Atrantil became the first clinical polyphenol formulation
The first investigation focused on gas and bloating. Research in agricultural and veterinary science had been examining how plant-derived compounds influence methane production in ruminant digestion. That literature raised an obvious question: if methane-producing organisms could be modulated through specific botanical chemistry in livestock, could the same mechanism apply to methane-associated digestive dysfunction in humans?
Working alongside clinical researcher Brandi Scott-Hoy, Dr. Brown began a structured investigation into polyphenol chemistry, microbial fermentation in the small intestine, and the role of methane-producing archaea in digestive symptoms. That work led to Atrantil, a polyphenol formulation built around Quebracho colorado, horse chestnut, and peppermint. Designed against the fermentation mechanism, not a list of symptoms. Atrantil entered structured clinical evaluation before "polyphenol" had become a consumer category.
How Re:flux addresses the pressure mechanism in reflux
The next investigation came from the clinic and from Dr. Brown's own clinical experience. Reflux is the most common condition in gastroenterology and the most over-treated. Long-term acid suppression dominates the standard of care, and the standard of care has known limitations. Patients return to symptoms when medication is reduced. The conversation almost always centers on acid.
The KBS Research investigation centered on pressure. Specifically, on lower esophageal sphincter function, intra-abdominal pressure, and motility. Reflux, in many cases, is a pressure event before it is a chemistry event. After eight years of formulation work, a combination of hesperidin, Atractylodes macrocephala, noni fruit, and dandelion root demonstrated pressure-modulating and motility-supporting activity consistent with the upper-GI literature. That formulation became Re:flux, the subject of a peer-reviewed publication.
From two formulations to a research framework
What started as two formulations became a framework. The gut is a system. Symptoms rarely exist in isolation, and isolated interventions rarely produce lasting resolution. Across more than a decade of work, four mechanisms emerged as the core drivers of digestive dysfunction: fermentation, pressure, movement, and balance.
KBS Research is built around that framework. Every formulation we bring to market addresses one of the four mechanisms, validates the approach in structured human studies, and publishes the results through peer review. We did not follow polyphenol research into a consumer category. We helped define the clinical use of polyphenols in gastrointestinal therapeutics. We are still defining it.
